Bispecific Antibodies in Hematological Malignancies: Teclistamab & Market Trends 2025
Teclistamab is revolutionizing treatment for hematological malignancies, with emerging market trends set to influence bispecific antibody therapies by 2025.
Medically Reviewed
by Dr. James Morrison, Chief Medical Officer (MD, FACP, FACC)
Reviewed on: April 28, 2026
Key Takeaways
- Main news: Bispecific antibodies like teclistamab, mosunetuzumab, and epcoritamab are transforming the treatment landscape for hematological malignancies.
- Clinical impact: These antibodies have demonstrated high overall response rates and are being explored in earlier lines of treatment, as highlighted at ASH 2025.
- Market implications: The expanding market for bispecific antibodies intensifies competition with CAR-T therapies and monoclonal antibodies.
- Next steps: Addressing real-world adoption barriers, such as managing adverse events and logistical considerations, will be crucial for the widespread integration of bispecific antibodies in clinical practice.
Bispecific antibodies, including teclistamab, mosunetuzumab, and epcoritamab, are rapidly changing the treatment paradigm for hematological malignancies. Updates presented at the 2025 American Society of Hematology (ASH) meeting underscored the high response rates and the shift towards using these agents in earlier lines of therapy; however, real-world adoption challenges persist. The teclistamab multiple myeloma treatment landscape is evolving, as is the approach to treating B-cell lymphomas and acute leukemias. Why it matters: These therapies offer new options for patients with previously difficult-to-treat cancers.
Drug Overview
Bispecific antibodies are a class of monoclonal antibodies engineered to bind to two different antigens simultaneously. These antibodies engage T cells via CD3 and tumor cells via specific antigens such as BCMA (B-cell maturation antigen) in the case of teclistamab, or CD20 in the case of mosunetuzumab and epcoritamab. Teclistamab is used in multiple myeloma, while mosunetuzumab and epcoritamab are used in B-cell lymphoma and acute leukemia. Brand names were not specified in the source.
Clinical Insights
Updates from ASH 2025 highlighted the efficacy of bispecific antibodies in treating hematological malignancies. Teclistamab has demonstrated significant efficacy in multiple myeloma, while mosunetuzumab and epcoritamab have shown promising activity in B-cell lymphomas and acute leukemias. The ASH data indicated high overall response rates (ORR) and a trend toward using these bispecific antibodies in earlier lines of treatment. Real-world adoption challenges include managing adverse events.
Regulatory Context
Specific regulatory approval dates, submission history, and pathways for teclistamab, mosunetuzumab, and epcoritamab were not explicitly provided. Safety and adverse event profiles are important for real-world adoption, but detailed safety signals, black-box warnings, or REMS requirements were not described.
Market Impact
The expanding market for bispecific antibodies in the US is driven by the unmet needs in treating multiple myeloma and B-cell lymphomas. These therapies face competition from CAR-T therapies and monoclonal antibodies. Adoption is influenced by efficacy, safety management, and logistical considerations. The hematological malignancies market is competitive, with bispecific antibodies offering a novel mechanism compared with existing CAR-T and monoclonal antibody therapies. Compared with CAR-T therapies, bispecific antibodies offer a different risk/benefit profile.
Future Outlook
Future trends in bispecific antibody development include exploring novel targets and combination regimens. There is potential for expansion into earlier lines of therapy and broader hematological malignancy indications. Addressing real-world adoption barriers, such as adverse event management protocols and healthcare infrastructure needs, will be crucial. What to watch next: Monitoring the evolving competitive dynamics and market growth trajectory over the next 3–5 years will provide insights into the sustained impact of bispecific antibodies.
Frequently Asked Questions
What are bispecific antibodies and how do they work?
Bispecific antibodies are a class of monoclonal antibodies engineered to bind to two different antigens simultaneously. They work by engaging T cells via CD3 and tumor cells via specific antigens such as BCMA (in the case of teclistamab) or CD20 (in the case of mosunetuzumab and epcoritamab).
What are the main challenges in adopting bispecific antibodies in clinical practice?
Real-world adoption challenges for bispecific antibodies include managing adverse events and logistical considerations in clinical practice.
What was highlighted at ASH 2025 regarding bispecific antibodies?
The 2025 ASH updates emphasized the movement of these bispecific antibodies into earlier lines of treatment and reported high overall response rates.
How do bispecific antibodies compare to CAR-T therapies?
Bispecific antibodies offer a different risk/benefit profile compared to CAR-T therapies, particularly in terms of ease of administration and management of side effects.
References
References
- U.S. Food and Drug Administration. FDA approval. Accessed 2026-04-28.
Senior Medical Editor
Dr. Sarah Chen is a board-certified internist and former FDA clinical reviewer with 15+ years of experience in pharmaceutical regulatory affairs. She received her MD from Johns Hopkins and her PhD in ...
About the Author
Related Articles
Bispecific Antibodies in Hematological Malignancies: Teclistamab, Mosunetuzumab & Epcoritamab FDA Review
Bispecific Antibody Therapies in B-Cell Lymphomas: FDA Approvals & Market Outlook
Bispecific Antibody Therapies in RRMM: Teclistamab & Emerging Trends (FDA 2025)
